8-K: Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides Business Update

Aptevo Therapeutics announced its third quarter 2024 financial results, highlighting clinical milestones and a $5.75 million capital raise.

Summary

• Aptevo Therapeutics reported its financial results for the third quarter of 2024, ending September 30, 2024.
• The company initiated the Phase 1b/2 RAINIER clinical trial for mipletamig in frontline acute myeloid leukemia (AML), building on positive dose escalation results.
• Interim data from the ALG.APV-527 Phase 1 trial in solid tumors was presented at the European Society for Medical Oncology (ESMO) Congress, with additional data to be presented at the Society for Immunotherapy of Cancer conference on November 8th.
• Aptevo raised $5.75 million through two financings during the quarter.
• The company's cash and cash equivalents totaled $7.8 million as of September 30, 2024.
• Research and development expenses decreased to $3.1 million for the quarter, down from $3.9 million in the same period of 2023.
• General and administrative expenses also decreased to $2.1 million, compared to $2.7 million in the third quarter of 2023.
• Aptevo reported a net loss of $5.1 million, or $0.48 per share, for the quarter, compared to a net loss of $6.3 million, or $22.16 per share, in the same period of 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant clinical progress and a successful capital raise, although the company is still operating at a loss. The positive clinical data and reduced losses are encouraging.

Positives

• The initiation of the Phase 1b/2 RAINIER trial for mipletamig is a significant step forward in its development.
• The interim data for ALG.APV-527 showing 60% of patients achieving stable disease is encouraging.
• ALG.APV-527 demonstrated a good safety profile.
• The company successfully raised $5.75 million in capital.
• Both research and development and general and administrative expenses decreased year-over-year.
• The net loss per share improved significantly from $22.16 to $0.48 year-over-year.

Negatives

• The company reported a net loss of $5.1 million for the quarter.
• Cash and cash equivalents decreased from $16.9 million at the end of 2023 to $7.8 million as of September 30, 2024.

Risks

• The company's future success depends on the outcome of its clinical trials.
• There is a risk that the final trial results may vary from the interim assessments.
• The company may face challenges in raising additional capital.
• Adverse events or unexpected safety issues during clinical trials could impact the development of their drug candidates.
• Changes in regulatory, social, macroeconomic and political conditions could affect the company's business.

Future Outlook

The company anticipates continued progress in its clinical programs and expects to build on the momentum achieved in the third quarter into 2025.

Management Comments

• Aptevo achieved significant clinical progress in both programs this quarter, marking important progress toward our mission and goals.
• We were thrilled to initiate the next phase of our mipletamig development program a robust Phase 1b/2 trial for frontline AML patients, combining mipletamig with the established standard of care, venetoclax and azacitidine.
• This trial structure is informed by the encouraging results from our dose expansion trial, reinforcing our belief in mipletamig's transformative potential for AML patients.
• We also released positive interim data on our solid tumor drug, ALG.APV-527, at the European Society of Medical Oncology conference in September that further underscores the impact of our innovation.
• In early clinical evaluation, our solid tumor targeting bispecific demonstrated safety, tolerability, and compelling activity, with 60% of evaluable patients achieving stable disease in monotherapy across challenging tumor types, including breast and colon cancer.
• The progress were witnessing, combined with nearly $6 million in capital secured in the quarter, sets a promising stage for the fourth quarter and lays the groundwork for continued successes into 2025.

Industry Context

This announcement is relevant to the immuno-oncology sector, where companies are focused on developing novel therapies for cancer treatment. Aptevo's progress in clinical trials and its proprietary ADAPTIR and ADAPTIR-FLEX platforms position it as a player in this competitive space.

Comparison to Industry Standards

• Aptevo's 60% stable disease rate in the ALG.APV-527 trial is a positive signal, but it is important to compare this to other similar bispecific antibody trials in solid tumors.
• Companies like Xencor and Regeneron are also developing bispecific antibodies, and their clinical trial results should be considered for a comprehensive comparison.
• The initiation of the Phase 1b/2 RAINIER trial for mipletamig is a significant step, but its success will depend on how it compares to other AML treatments, including those using venetoclax and azacitidine.
• The $5.75 million capital raise is relatively small compared to larger biotech companies, but it is a positive sign for a company of Aptevo's size.

Stakeholder Impact

• Shareholders may view the clinical progress and capital raise positively.
• Employees may be encouraged by the company's progress and future prospects.
• Patients may benefit from the development of new cancer therapies.
• Creditors may be reassured by the company's financial stability and progress.

Next Steps

• Aptevo will continue the Phase 1b/2 RAINIER trial for mipletamig.
• Additional data from the ALG.APV-527 trial will be presented at the Society for Immunotherapy of Cancer conference on November 8th.
• The company will continue to advance its clinical programs and seek further funding.

Key Dates

Keywords

Aptevo Therapeutics, clinical trials, immuno-oncology, mipletamig, ALG.APV-527, acute myeloid leukemia, solid tumors, biotechnology, financial results, ADAPTIR, ADAPTIR-FLEX